Thursday, November 10, 2016 7:56:06 AM
Nov. 10, 2016 7:52 AM ET|About: Bristol-Myers Squibb C... (BMY)|By: Douglas W. House, SA News Editor
A Phase 3 clinical trial, ONO-4538-12, assessing Bristol-Myers Squibb's (NYSE:BMY) Opdivo (nivolumab) for the treatment of patients with unresectable advanced or recurrent gastric cancer resistant to standard therapy met its primary endpoint of overall survival (OS). The company says this is the first immuno-oncology agent to show such a benefit in these patients.
Bristol-Myers and development partner Ono Pharmaceutical Co. Ltd. are working with investigators on the future presentation of the results.
Opdivo is currently approved for the treatment of non-small cell lung cancer, melanoma, kidney cancer and classical Hodgkin lymphoma. It is BMY's fastest growing product and is poised to overtake top-selling Eliquis in the near future. Over the past four quarters, Opdivo's sales were $2.929B compared to $2.997B for Eliquis.
_____________________________________________
http://seekingalpha.com/news/3223294-bristol-myers-opdivo-successful-late-stage-gastric-cancer-study
BMY
Recent BMY News
- A Bristol Myers Squibb Expande as Iniciativas de Doações para a Equidade em Saúde a fim de Melhorar os Resultados de Saúde • Business Wire • 03/26/2024 06:25:00 PM
- Bristol Myers Squibb Expands Health Equity Grant Initiatives to Improve Health Outcomes • Business Wire • 03/26/2024 10:59:00 AM
- Bristol Myers Squibb to Present Data at the American College of Cardiology Annual Scientific Session 2024 Reinforcing Extensive Body of Evidence in Clinical and Real-World Settings Across Cardiovascular Portfolio • Business Wire • 03/25/2024 12:00:00 PM
- Bristol Myers Squibb’s Abecma (idecabtagene vicleucel) Becomes First CAR T Cell Therapy Approved in the European Union in Earlier Lines for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma • Business Wire • 03/20/2024 08:45:00 PM
- Bristol Myers Squibb Announces CheckMate -9DW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Meets Primary Endpoint of Overall Survival for the First-Line Treatment of Advanced Hepatocellular Carcinoma • Business Wire • 03/20/2024 10:59:00 AM
- Bristol Myers Squibb and Ted Danson Empower Those with Plaque Psoriasis to Take Action in “SO, Have You Found It?” Campaign • Business Wire • 03/19/2024 10:59:00 AM
- Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience Portfolio • Business Wire • 03/18/2024 12:44:00 PM
- FDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy • Business Wire • 03/15/2024 10:27:00 PM
- U.S. FDA Approves Bristol Myers Squibb’s Breyanzi® as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) • Business Wire • 03/15/2024 01:35:00 AM
- Bristol Myers Squibb to Report Results for First Quarter 2024 on April 25, 2024 • Business Wire • 03/11/2024 08:16:00 PM
- U.S. Food and Drug Administration Approves Opdivo® (nivolumab), in Combination with Cisplatin and Gemcitabine, for First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma • Business Wire • 03/07/2024 07:23:00 PM
- Bristol Myers Squibb to Participate in Upcoming Investor Conferences • Business Wire • 03/06/2024 09:17:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 10:57:57 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 10:52:54 PM
- Bristol Myers Squibb Announces Dividend • Business Wire • 03/01/2024 09:16:00 PM
- Bristol Myers Squibb Announces New Data from the Long-Term DAYBREAK Study Reinforcing Efficacy and Safety of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Sclerosis • Business Wire • 02/29/2024 11:59:00 AM
- Bristol Myers Squibb to Participate in the TD Cowen 44th Annual Health Care Conference • Business Wire • 02/26/2024 09:16:00 PM
- Bristol Myers Squibb Completes Acquisition of RayzeBio, Adding Differentiated Actinium-Based Radiopharmaceutical Platform • Business Wire • 02/26/2024 01:35:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 11:03:45 PM
- Form SC TO-T/A - Tender offer statement by Third Party: [Amend] • Edgar (US Regulatory) • 02/23/2024 12:34:04 PM
- Bristol Myers Squibb Announces Expiration of RayzeBio Tender Offer • Business Wire • 02/23/2024 11:59:00 AM
- Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl® (luspatercept) for Treatment of Adults with Transfusion-Dependent Anemia due to Low- to Intermediate-Risk Myelodysplastic Syndromes (MDS) • Business Wire • 02/23/2024 11:59:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 09:15:35 PM
- U.S. Food and Drug Administration (FDA) Accepts Supplemental New Drug Application for KRAZATI® (adagrasib) in Combination with Cetuximab as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or... • Business Wire • 02/20/2024 11:59:00 AM
- Bristol Myers Squibb Prices $13 Billion of Senior Unsecured Notes • Business Wire • 02/15/2024 12:57:00 AM
FEATURED POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • Mar 27, 2024 10:52 AM
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM